Sondra. welcome year-end everybody thanks morning Great, our and XXXX Good update. to
finished are way We organic quarter, delighted in XX% the year, year for XX% coming company for full with growth in the the organic the we growth at with off overall XX%. growth XXXX the and fourth
highly in with quarter base customers on the the for to our enabling technologies. of we the Our continues business growth an was for for core continued bioprocess to of products as our company and year, Overall, reflecting XX% deliver accelerated our COVID year XX% growth demand strategy outstanding top with above-market XXXX business tailwinds. execute on differentiated
highlights. the Let’s cover of some key
the front, On the we management with position Avitide with deal. acquisition, our Solutions deal, strengthened proteins with in infiltration the M&A BioFlex market in the and fluid Polymem
customers meaningful the increased being also very ongoing approximately $XXX leading bioprocessing, share key our across in reputation all three industry positioned The a and manufacturers. gene capacity COVID the well lines. many innovation targeting between and therapy the a Operationally, company enter as product this gene growth. to a with increased This market are with in of in support which recognition, portfolio pandemic strong take capacity our our products, additional We leader in exceptional growth, to with delivering against nine-fold XXXX our the new adoption as to we base us of growing brand a driver major supported business allowed way million the therapy. by vaccine we was fight product
and M&A COVID Our to in over our XXXX, by business allowed billion to $X has driven market XXXX total billion that in acceleration, $X.X us from addressable market markets. expansion, increased expand significantly base
Finally, XXXX sustainability We first in safety, of published was and QX. DEI. area all commitment our the report sustainability in increased about
the the and at baseline diversity key use sites, launch in XXX% report XXXX, our renewable highlights renewable focus energy inclusion to of and we reduction recycling include initiatives, on to Some the conversion four In a DEI XX% sites, moving in and carbon programs. energy XXXX, at will single of in our year efforts XXX% emissions our additional initiative. versus packaging,
few increasing for building minutes the beginning that out our have QX I strategic year. one into initiatives was spend to the jumping and unit growth. our around around support our was Three technologies was pipeline, business full around four of disruptive integrating we highlights highlighted EMT, Repligen. and launching on traction Before year, capacity in ARTeSYN at and Number want was the a Number R&D market from two business our into NMS to around gene therapy. our
our with start on Let’s progress capacity.
in capacity our to and expand lines. Our was especially the was our goal, like rapidly of expansion fiber The at site over the the combination filtration peers, of our Polymem our nine-fold. made area increased of many where significant, capacity programs progress we acquisition hollow the across product Rancho
industry complete we our of from combination XX% the an last capacity space of expansion of of and filtration spend Marlborough million we fluid facility year columns. of our our gene in for new expect $XX in Rancho new we filtration majority growth therapy additional XXXX. to application with XX% XXXX. management our This on our in XXX increased the efforts growth customers and European the and the during We center OPUS our We north for driven accomplished in first adding With year, In to from site efficiency a increased plans. by end manufacturing also the to Massachusetts. presence our increased expansion close about XXXX, a million to for gene prepacked process portfolios accounts market had Asia. more and year. adding opening we up with Breda workforce. be approximately our focused and expect therapy, analytics qualified center on production In running and finished Hopkington, of brought up XX% assembly includes XX successfully customers, up XXXX, here scale-up, cell European and and online accounts, acquiring $XX XX and came by Much to of XXXX We our focus in in and of significant what overall in traction
In continue be in three programs. a to products New on core strategy. our overall pillar team key our delivered R&D XXXX,
inline launching around base analytics is platform, was on a quickly which the first The by system our GMP-compliant adopted FlowVPX been has manufacturing floor. the which customer
monoclonal effectively to to around Purolite the was standardized with overcoming Second a and launch A purify first challenges, industry’s was and antibodies, our aggregation deliver on ARTeSYN Navigo pH-sensitive Sciences chromatography custom Life optimizing protein third the of resin working to portfolio systems. systems
year of our R&D as a of bioprocessing strong the filtration on another AAV be reinforcing to expanding XXXX as family we our resins, which systems, leader. we ARTeSYN expect and launching week, for focus position this family announced We innovation earlier in
XXXX ARTeSYN Repligen our with NMS products. use New into Waterford, the business key while pro Finally was came on for single a The to way Ireland in of integration to the integration internal us York Park, for expected, performance in and the flow Clifton front, in approximately combined EMT of paths both up XX% industry. and as we and very meaningful successfully growing sites the basis in manufacturing forma address of our integration The build-out a ARTeSYN a of need completed contributing Repligen. EMT, focus the on
a products addition we plan into and products Solutions to the the XXXX, here broad of these we a With late of move BioFlex in company in for new portfolio have now fluid XXXX. management franchise
demonstrating revenue traction from facility. and and of our by demand vaccine XX% for four XX delivering the business growth, products, quarter the year had performance, revenue growth accelerated Within especially our we second quarter last QX quarter. position all quarter. total performance a growth in nearly output the for points Moving and year, in driven therapy in demand revenues COVID $XXX increased increased our as XX% XX%,with full half our production and now coming overall million reported base COVID quarter of to exceptional the for in in COVID-related business Polymem the reinforcing from increased our with up revenues XX% the record and were or in today, accounted also year. gene sales of franchises customers approximately of market
the revenue. year, our For revenues COVID of increased to overall million, representing $XXX XX%
demand strong see to $XXX to base year. and COVID accounts for our continued COVID this that expect $XXX contribute from revenues the company We customer million million will in
for orders XX% were were up were growing stellar with year-on-year over the business base orders orders down a the In at of the QX majority orders QX COVID of a business front, base XXXX. we when the placed. in tough comp Sequentially, up XX% year On quarter, COVID off approximately orders following finished XX%. XXXX
in is line order and COVID over for $XXX XXXX million much with Our expectations our year. the now book for very
this Moving prepacked proteins systems, to report now ARTeSYN are from in into date chromatography placing of to will chromatography, better and Avitide our to been franchise-level Affinity columns, with business, franchise resins, our we align have of Affinity and franchise which performance, where ligands our consist as OPUS revenue ELISA chromatography kits.
the as columns commercial customers XX% demand if Avitide by continues challenge In have seen are OPUS our lead more and had the we up year up throughout quarter with stage XX%. dealing including into revenues XX% contribution and solid largest the be chromatography, from year OPUS availability XX approximately and Our we chromatography put OPUS vaccines. included. on XXXX the was excluding processes, these extended times for for year, were the resin suppliers. COVID a resins, quarter from top for late full The main strong our and to Affinity business and Within products increased the
accelerate supply this in XXXX, we OPUS growth half move of We year. will which will expect as the that resin through for improve the second issue
our of in expect to the chromatography XX% grow range XX% We for franchise XXXX. to
year fronts. strong year quarter Our executed the Affinity finished XXXX was and XX% for approximately excluded. franchise and XX% another and resins many pivotal had we as proteins Avitide strategically a included with on us up
new demand high from NGL be in Cytiva; launched Overall, third, decrease continued we Avitide, will proteins in be mostly X% for down the increasing our supply we Cytiva and ligands. Affinity new marketplace ligand In developed Avitide XXXX. and will First, and and by acquired that traction expect offset pH with to resin content. approximately XXXX, NGL expect second, with revenue we agreement our Purolite; a we we signed a our
therapy growth KrosFlo cassette, Our the of up and for The speccing-in demand. year. the commercial sheet flat for for filtration franchise XCell was our the Key over the Repligen our marketplace gene and momentum drugs, the quarter the and year of generation in the in new the included the FS the XXX% continued into big story sheet of more quarter XXXX, in ATF system highlights in driver XXX% the than launch next cassettes, hollow flat products. acceleration quarter fiber systems and for in multiple was
the in of For the about significant revenues vaccine in our strong growth in in expect we grow of franchise saw year, XX% XX% the With franchise overall XX% filtration range to the momentum comprised marketplace, will revenue. COVID XXXX. we which
had was year outstanding cell analytics quarter especially an and our QX for new technology of quarter therapy. application for in XX% commercial Finally, franchise has approximately and VP areas, new revenues process year. account gene and represented into the expanded Revenue over and driving XXXX. The on our development, the which XX% growth in team focused XX%
Overall, encouraged base FlowVPX to XX% XX%. the strong XX% of business we year XX% XX% we company of to by strong to in including XX%. growth and expect to be growth of to analytics at with growth range continue XXXX, be XXXX organic XX% another grow adoption in the expect of for to approximately and We the
strategic the accelerating BioFlex Polymem, finally about and will our our around Number will next be around following. on launching the Solutions. and are will new further gene three accounts. confident in to well hitting traction years, to resins As AAV we year, four growth successfully share we out therapy ARTeSYN in businesses. XXXX. move gain priorities goal one number Number dollars integrating building be cell TFF by including Number be around of three support the systems, positioned our center products, we capacity will are bioprocessing through to two will our and billion and believe five at market and We be a over continued Avitide on
in want and X,XXX-plus including year. the their to to commitment wish Polymem, our our also and I look for around part as shareholders concluding, Avitide, strong customers new for leadership our employees here loyal their at Before globe, and colleagues BioFlex forward year Solutions last XXXX. in success to Repligen’s another thank delivering I we recognize
Jon to a Now call the performance. report for like to on turn over I’d financial our
